These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33601485)

  • 1. [Construction of artificial neural network model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer].
    Lin SM; Wang XJ; Huang SH; Xu ZB; Huang Y; Lu XR; Xu DB; Chi P
    Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):202-206. PubMed ID: 33601485
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
    Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
    J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
    Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
    Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
    Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
    Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model.
    Zhang Y; Xu M; Sun Y; Chen Y; Chi P; Xu Z; Lu X
    Front Cell Dev Biol; 2020; 8():609832. PubMed ID: 33585448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
    He J; Cheng J; Guan Q; Yan H; Li Y; Zhao W; Guo Z; Wang X
    Cancer Sci; 2020 Jan; 111(1):253-265. PubMed ID: 31785020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
    BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
    Abdel-Rahman O
    Clin Transl Oncol; 2019 Apr; 21(4):512-518. PubMed ID: 30182209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks.
    Yuan Y; Tan CW; Shen H; Yu JK; Fang XF; Jiang WZ; Zheng S
    Hepatogastroenterology; 2012; 59(120):2461-5. PubMed ID: 22497949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer.
    Yang Y; Zhang J; Zhang W; Wang Y; Zhai Y; Li Y; Li W; Chang J; Zhao X; Huang M; Geng Q; Yang Y; Gong Z; Yu N; Shen W; Li Q; Huang S; Guo W
    Mol Cancer; 2023 Dec; 22(1):199. PubMed ID: 38062470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.